Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system

被引:3
|
作者
Lettino, M
Cantù, F
Mariani, M
机构
[1] IRCCS, Policlin S Matteo, CCU Cardiol, Dept Cardiol, I-27100 Pavia, Italy
[2] Univ Pisa, Inst Cardiol, Cardiothorac Dept, Pisa, Italy
关键词
aspirin; atherosclerosis; cyclo-oxygenase; endothelial cells; platelets; prostaglandin;
D O I
10.1016/S1590-8658(01)80154-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Prostaglandins play important roles in the pathophysiological mechanism of action of platelets and endothelial cells in the cardiovascular system. The two isoforms of cyclo-oxygenase, respectively cyclo-oxygenase-1 and cyclo-oxygenase-2, are differently expressed in these cells. Activated platelets show a relatively large amount of cyclo-oxygenase-1, whereas endothelial cells have the gene for cyclo-oxygenase-2, the expression of which follows cell activation. In the atherosclerosis lesion, prostaglandin synthesis is mainly mediated by the inducible cyclo-oxygenase-2 expressed in macrophages/foam cells, smooth muscle cells and endothelial cells. Aspirin, a selective platelet cyclo-oxygenase-1 inhibitor, still remains the most extensively studied antiplatelet agent, even though there is growing evidence that many other compounds could be valuable either in association, or alternatives in antithrombotic therapy.
引用
收藏
页码:S12 / S20
页数:9
相关论文
共 50 条
  • [21] Clinical potential of cyclo-oxygenase-2 inhibitors
    Oviedo, JA
    Wolfe, MM
    BIODRUGS, 2001, 15 (09) : 563 - 572
  • [22] The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene
    McGettigan, Patricia
    Lincz, Lisa F.
    Attia, John
    McElduff, Patrick
    Bissett, Linda
    Peel, Roseanne
    Stokes, Barrie
    Hancock, Stephen
    Henderson, Kim
    Seldon, Michael
    Henry, David
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (04) : 707 - 714
  • [23] CARDIOVASCULAR AND GASTROINTESTINAL TOXICITY OF SELECTIVE CYCLO-OXYGENASE-2 INHIBITORS IN MAN
    Dajani, E. Z.
    Islam, K.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2008, 59 : 117 - 133
  • [24] Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?
    Bing, RJ
    Lomnicka, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (03) : 521 - 522
  • [25] Cyclo-oxygenase-1 and-2 contribution to endothelial dysfunction in ageing
    Heymes, C
    Habib, A
    Yang, D
    Mathieu, E
    Marotte, F
    Samuel, JL
    Boulanger, CM
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (04) : 804 - 810
  • [26] Effects of selective inhibitors of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) on the spontaneous myogenic contractions in the upper urinary tract of the guinea-pig and rat
    Davidson, ME
    Lang, RJ
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (04) : 661 - 670
  • [27] Nonsteroid drug selectives for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity:: A full in vitro analysis (vol 96, pg 7563, 1999)
    Warner, TD
    Giuliano, F
    Vojnovic, I
    Bukasa, A
    Mitchell, JA
    Vane, JR
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) : 9966 - 9966
  • [28] Differential metabolism of dihomo-γ-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2:: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2
    Levin, G
    Duffin, KL
    Obukowicz, MG
    Hummert, SL
    Fujiwara, H
    Needleman, P
    Raz, A
    BIOCHEMICAL JOURNAL, 2002, 365 (02) : 489 - 496
  • [29] Pharmacokinetics of RofecoxibA Specific Cyclo-Oxygenase-2 Inhibitor
    Neal M. Davies
    Xiao W. Teng
    Neil M. Skjodt
    Clinical Pharmacokinetics, 2003, 42 : 545 - 556
  • [30] Cyclo-Oxygenase-2 InhibitorsWhen Should They Be Used in the Elderly?
    Ruth Savage
    Drugs & Aging, 2005, 22 : 185 - 200